Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 2, 2002, Pages 205-211

  Saad, Everardo D ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Autologous; Neoplasms; Unknown primary drug therapy transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PACLITAXEL;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG MEGADOSE; EUROPE; HUMAN; HYPOTHESIS; IDIOPATHIC DISEASE; PROGNOSIS; REVIEW; SOLID TUMOR; STRATIFICATION; TUMOR; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS;

EID: 0036169186     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00157-3     Document Type: Review

References (26)

1. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients
2. Metastatic cancer of unknown primary site
3. An analysis of 1539 patients with cancer of unknown primary site
4. Cancer of unknown primary site
5. Metastases of unknown primary site
6. Analysis of a diagnostic strategy for patients with suspected tumors of unknown primary origin
7. Treatment of patients with cancer of an unknown primary site
8. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma
9. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma
10. Unknown primary squamous cell carcinoma metastatic to the neck
11. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin
12. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity
13. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome
14. Undifferentiated carcinoma in young men: the atypical teratoma syndrome
15. The unrecognized extragonadal germ cell cancer syndrome
16. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience
17. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
18. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide
19. Treatment of the patient with adenocarcinoma of unknown origin
20. Metastatic adenocarcinoma of unknown primary site
21. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site
22. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study
23. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary
24. Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors
25. Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy